Successful Response to the Combination of Immunotherapy and Chemotherapy in Cholangiocarcinoma with High Tumour Mutational Burden and PD-L1 Expression: a Case Report

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 Nov 14

PMID 30419854

Citations 30

Authors

Haibo Mou

Lanfang Yu

Qin Liao

Xuehua Hou

Yinfang Wu

Qiang Cui

Na Yan

Ruobing Ma

Lingjian Wang

Ming Yao

Kai Wang

Affiliations

Soon will be listed here.

Abstract

Background: Cholangiocarcinoma, or bile duct cancer, is a gastrointestinal cancer with limited therapeutic options and a poor outcome. Studies have revealed that some major driver genes are associated with cholangiocarcinoma, but no targeted therapies have been approved. Immune checkpoint inhibitors, which are represented by inhibitors of programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), have emerged as a potential therapy for multiple types of solid cancers.

Case Presentation: A 53-year-old female presented with postoperative recurrence of PD-L1-positive intrahepatic cholangiocarcinoma with a high tumour mutational burden. This patient exhibited a marked response to the combination of anti-PD-1 immunotherapy and chemotherapy.

Conclusions: As far as we know, this is the first case report on the success of the combination of immunotherapy and chemotherapy for advanced cholangiocarcinoma with PD-L1 positivity and a high tumour mutational burden.

Citing Articles

Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma.

Gao L, Gao J, He J, Fan W, Che X, Wang X Sci Rep. 2025; 15(1):4412.

PMID: 39910141 PMC: 11799344. DOI: 10.1038/s41598-025-88671-4.

Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on....

Song L, Qingdong W, Shunhang Y, Long L, Guangsheng Z, Guangji Y World J Surg Oncol. 2025; 23(1):21.

PMID: 39856751 PMC: 11761194. DOI: 10.1186/s12957-025-03679-4.

Research hotspots and trends in immunotherapy for cholangiocarcinoma: a bibliometric analysis (2014-2023).

Qu X, Wang Q, Zhu F, Liang H, Long Z, Wu Y Front Immunol. 2024; 15:1436315.

PMID: 39660136 PMC: 11628549. DOI: 10.3389/fimmu.2024.1436315.

Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case.

Zhang H, Yu H Front Oncol. 2024; 14:1428370.

PMID: 39077469 PMC: 11284616. DOI: 10.3389/fonc.2024.1428370.

Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).

Yang S, Zou R, Dai Y, Hu Y, Li F, Hu H Int J Oncol. 2023; 63(6).

PMID: 37888583 PMC: 10631767. DOI: 10.3892/ijo.2023.5585.

References

Iwai Y, Hamanishi J, Chamoto K, Honjo T . Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017; 24(1):26. PMC: 5381059. DOI: 10.1186/s12929-017-0329-9. View

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Viale G, Trapani D, Curigliano G . Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. Biomed Res Int. 2017; 2017:4719194. PMC: 5523547. DOI: 10.1155/2017/4719194. View

Maleki Vareki S, Garrigos C, Duran I . Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017; 116:116-124. DOI: 10.1016/j.critrevonc.2017.06.001. View

Dodson R, Weiss M, Cosgrove D, Herman J, Kamel I, Anders R . Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013; 217(4):736-750.e4. DOI: 10.1016/j.jamcollsurg.2013.05.021. View

Hodges T, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S . Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017; 19(8):1047-1057. PMC: 5570198. DOI: 10.1093/neuonc/nox026. View

Farley D, Weaver A, Nagorney D . "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc. 1995; 70(5):425-9. DOI: 10.4065/70.5.425. View

Takakura H, Domae S, Ono T, Sasaki A . The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma. Acta Med Okayama. 2017; 71(3):219-226. DOI: 10.18926/AMO/55204. View

Flejou J . [WHO Classification of digestive tumors: the fourth edition]. Ann Pathol. 2011; 31(5 Suppl):S27-31. DOI: 10.1016/j.annpat.2011.08.001. View

10.

Ribas A, Hamid O, Daud A, Hodi F, Wolchok J, Kefford R . Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016; 315(15):1600-9. DOI: 10.1001/jama.2016.4059. View

11.

Loaiza-Bonilla A, Clayton E, Furth E, OHara M, Morrissette J . Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience. 2014; 8:479. PMC: 4239128. DOI: 10.3332/ecancer.2014.479. View

12.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

13.

Rijnders M, de Wit R, Boormans J, Lolkema M, van der Veldt A . Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017; 72(3):411-423. DOI: 10.1016/j.eururo.2017.06.012. View

14.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

15.

Langer C, Gadgeel S, Borghaei H, Papadimitrakopoulou V, Patnaik A, Powell S . Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016; 17(11):1497-1508. PMC: 6886237. DOI: 10.1016/S1470-2045(16)30498-3. View

16.

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

17.

Emens L, Ascierto P, Darcy P, Demaria S, Eggermont A, Redmond W . Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017; 81:116-129. DOI: 10.1016/j.ejca.2017.01.035. View

18.

Ahn S, Ansari A, Kim J, Kim D, Chun S, Kim J . The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget. 2016; 7(42):68638-68649. PMC: 5356579. DOI: 10.18632/oncotarget.11862. View

19.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

20.

Lehman J, Gwin M, Massion P . Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. Curr Oncol Rep. 2017; 19(7):49. DOI: 10.1007/s11912-017-0609-2. View